SS-31 (50 mg Vial) Dosage Protocol

Quickstart Highlights

SS‑31 (elamipretide) is a mitochondria‑targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane^[1], stabilizing electron transport chain complexes and reducing reactive oxygen species production while enhancing ATP synthesis^[2]. This peptide has demonstrated protective effects in preclinical models of heart failure, neurodegenerative disease, and age‑related muscle atrophy, and received FDA accelerated approval in 2025 as the first treatment for Barth syndrome^[3]. This educational protocol presents a once‑daily subcutaneous approach using the cost‑effective 50 mg vial format with practical reconstitution for insulin‑syringe measurements.

Reconstitute: Add 3.0 mL bacteriostatic water → ~16.67 mg/mL concentration for convenient dosing.

Typical daily range: 5–10 mg once daily (gradual titration); advanced protocols may reach 15–20 mg/day under supervision.

Easy measuring: At 16.67 mg/mL, 1 unit = 0.01 mL ≈ 167 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3.0 mL = ~16.67 mg/mL)

Week	Daily Dose	Units (per injection) (mL)
Weeks 1–2	5 mg (5000 mcg)	30 units (0.30 mL)
Weeks 3–8	10 mg (10,000 mcg)	60 units (0.60 mL)

Frequency: Inject once daily subcutaneously at a consistent time. This 50 mg vial reconstituted with 3.0 mL provides a higher concentration, keeping all standard doses within moderate syringe volumes for convenience and accuracy.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid vigorous shaking to prevent foaming.

Gently swirl/roll until fully dissolved (clear solution).

Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 4 weeks.

Advanced / Aggressive Approach (3.0 mL = ~16.67 mg/mL)

Week	Daily Dose	Units (per injection) (mL)
Weeks 1–2	5 mg (5000 mcg)	30 units (0.30 mL)
Weeks 3–4	10 mg (10,000 mcg)	60 units (0.60 mL)
Weeks 5–8	15 mg (15,000 mcg)	90 units (0.90 mL)
Optional Weeks 9–12	20 mg (20,000 mcg)	Split: 2 × 60 units (0.60 mL each)

Note: Advanced dosing (15–20 mg/day) is based on short‑term clinical trial protocols^[4]^[5] for severe mitochondrial conditions and should only be pursued under medical supervision. At this concentration, doses up to 15 mg fit in a single syringe (90 units); 20 mg doses should be split into two separate subcutaneous injections at different sites. Clinical trials have not extensively evaluated SS‑31 beyond 12 weeks; extended use requires careful monitoring.

Important: This guide is for educational purposes only and is not medical advice.

Supplies Needed

Plan based on an 8–12 week daily protocol with gradual titration using 50 mg vials.

Peptide Vials (SS‑31, 50 mg each):

8 weeks (Standard: 5–10 mg/day) ≈ 10 vials
12 weeks (Standard maintenance at 10 mg/day) ≈ 16 vials
12 weeks (Advanced: escalating to 15 mg/day) ≈ 21 vials

Insulin Syringes (U‑100, 1 mL capacity):

Per week (standard dosing): 7 syringes (1/day)
8 weeks: 56 syringes
12 weeks: 84 syringes
Advanced protocols with split injections may require 2 syringes per day for 20 mg doses

Bacteriostatic Water (30 mL bottles): Use 3.0 mL per vial for reconstitution.

8 weeks (10 vials): 30 mL → 1 × 30 mL bottle
12 weeks (16 vials): 48 mL → 2 × 30 mL bottles
12 weeks (21 vials, advanced): 63 mL → 3 × 30 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)
8 weeks: 112 swabs → recommend 2 × 100‑count boxes
12 weeks: 168 swabs → recommend 2 × 100‑count boxes

View Supplier

Protocol Overview

Concise summary of the once‑daily subcutaneous regimen.

Goal: Support mitochondrial function, enhance ATP production, and reduce oxidative stress in tissues with high metabolic demand^[1]^[2].

Schedule: Daily subcutaneous injections for 8–12 weeks (clinical trials typically 4–12 weeks).

Dose Range: 5–10 mg daily (standard); 15–20 mg daily (advanced, under supervision).

Reconstitution: 3.0 mL per 50 mg vial (~16.67 mg/mL) for convenient single‑syringe administration at standard doses.

Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 4 weeks.

Research Disclaimer

SS-31 (50mg Vial) Dosage Protocol